首页> 外文期刊>Antiviral Research >Entry inhibitors in the treatment of HIV-1 infection.
【24h】

Entry inhibitors in the treatment of HIV-1 infection.

机译:进入抑制剂用于治疗HIV-1感染。

获取原文
获取原文并翻译 | 示例
       

摘要

Infection of target cells by HIV is a complex, multi-stage process involving attachment to host cells and CD4 binding, coreceptor binding, and membrane fusion. Drugs that block HIV entry are collectively known as entry inhibitors, but comprise a complex group of drugs with multiple mechanisms of action depending on the stage of the entry process at which they act. Two entry inhibitors, maraviroc and enfuvirtide, have been approved for the treatment of HIV-1 infection, and a number of agents are in development. This review covers the entry inhibitors and their use in the management of HIV-1 infection. This article forms part of a special issue of Antiviral Research marking the 25th anniversary of antiretroviral drug discovery and development, Vol 85, issue 1, 2010.
机译:HIV对靶细胞的感染是一个复杂的多阶段过程,涉及到宿主细胞的附着以及CD4结合,共受体结合和膜融合。阻断HIV进入的药物被统称为进入抑制剂,但根据其所处的进入过程的阶段,其包含具有多种作用机理的复杂药物。两种进入抑制剂maraviroc和enfuvirtide已被批准用于治疗HIV-1感染,许多药物正在研发中。这篇综述涵盖了进入抑制剂及其在HIV-1感染管理中的用途。本文是《抗病毒研究》特刊(纪念抗逆转录病毒药物发现和开发25周年)的一部分,第85卷,第1期,2010年。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号